Dermira: A Snapshot of Financial Health and Future Prospects
Dermira, a prominent name in the biopharmaceutical industry, specializes in the development and commercialization of therapeutic solutions for dermatologic diseases. As of now, the company's stock stands firm at a price of $18.75, marking a stable phase in its market performance. Operating under the vast umbrella of Eli Lilly and Company, Dermira boasts a dedicated workforce of 333 employees and plays a significant role in the pharmaceutical sector.
When diving into the financial nuances of Dermira, the balance sheet reveals some interesting figures. For the nine months ending September 30, 2019, a net change in cash of -$30.22 million was noted. This figure provides insight into the company's monetary movements and is crucial for stakeholders to understand. The cash flow dynamics are a mixed bag, with positive cash flow seen in operating and financing activities, juxtaposed with a negative cash flow stemming from investing activities. These elements together paint a comprehensive picture of the company's current financial standing.
Support authors and subscribe to content
This is premium content. Subscribe to read the entire article.
